Literature DB >> 25814076

CML--Where do we stand in 2015?

Rüdiger Hehlmann1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25814076     DOI： 10.1007/s00277-015-2331-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  6 in total

Review 1.  [WHO classification of myeloid neoplasms].

Authors:  C Wickenhauser
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

2.  Innovation in hematology. Perspectives: CML 2016.

Authors:  Rüdiger Hehlmann
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

3.  Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.

Authors:  Michael Lauseker; Roman Gerlach; Martin Tauscher; Joerg Hasford
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-16       Impact factor: 4.553

4.  Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.

Authors:  H Hjorth-Hansen; J Stentoft; J Richter; P Koskenvesa; M Höglund; A Dreimane; K Porkka; T Gedde-Dahl; B T Gjertsen; F X Gruber; L Stenke; K M Eriksson; B Markevärn; A Lübking; H Vestergaard; L Udby; O W Bjerrum; I Persson; S Mustjoki; U Olsson-Strömberg
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

5.  Chronic myelogenous leukemia on target.

Authors:  Veronika Némethová; Filip Rázga
Journal:  Cancer Med       Date:  2018-06-14       Impact factor: 4.452

6.  Impact of frontline treatment approach on outcomes of myeloid blast phase CML.

Authors:  Kapil Saxena; Elias Jabbour; Ghayas Issa; Koji Sasaki; Farhad Ravandi; Abhishek Maiti; Naval Daver; Tapan Kadia; Courtney D DiNardo; Marina Konopleva; Jorge E Cortes; Musa Yilmaz; Kelly Chien; Sherry Pierce; Hagop Kantarjian; Nicholas J Short
Journal:  J Hematol Oncol       Date:  2021-06-15       Impact factor: 17.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.